• About ArQule
• Product R & D
• Clinical Trials
• Investors and Media
  • Press Releases
  • Events
  • Corporate Presentation
  • Recent Data Presentations
  • Corporate Governance
  • Financial Information
  • Stock Information
  • Contact Us
• Careers

Investors and Media

Our mission as a biotechnology company is to research, develop and commercialize a next-generation of small molecule cancer therapeutics. We are combining innovative, proprietary anti-cancer technology with world-class chemistry capabilities to generate drug candidates that target multiple tumor types, act selectively against cancer cells and are well tolerated by patients. Our lead products are in clinical development, and our research pipeline targets multiple molecules with established roles and therapeutic potential in cancer.

We are headquartered and operate research facilities and development programs in Woburn, Massachusetts.

 

Recent Releases

Jan 17, 2012
ArQule Announces Tivantinib Meets Primary Endpoint, Significantly Extending Time to Progression in Phase 2 Trial in Second-Line Hepatocellular Carcinoma

Dec 6, 2011
ArQule, Inc. to Present at Oppenheimer 22nd Annual Healthcare Conference

Recent Events

Jan 17, 2012 at 9:00 AM ET
ArQule, Inc. Conference Call to Discuss Phase 2 Results of Tivantinib HCC Trial

Corporate Presentation

Dec 14, 2011

View Presentation 744.4 KB

Stock Chart	Stock Quote
3 Mo.   6 Mo.   1 Yr.	ArQule NASDAQ: ARQL Price: 8.14 Change: + 0.13 Day High: 8.19 Day Low: 7.98 Volume: 563,600 Delayed at least 20 minutes. Provided by eSignal.

Transfer Agent
American Stock and Transfer
41 Wall Street
New York City, NY 10005
Phone: 212-936-5100